Halaven® (Eribulin) Receives Positive CHMP Opinion in Advanced Liposarcoma Following Significant Phase III Data (y 2)

Our commitment to meaningful progress in oncology research, built on scientific expertise, is supported by a global capability to conduct discovery and preclinical research, and develop small molecules, therapeutic vaccines, and biologic and supportive care agents for cancer across multiple indications.

About Eisai Co., Ltd. 

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With over 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realise our hhc philosophy by delivering innovative products in multiple therapeutic areas with high unmet medical needs, including Oncology and Neurology. 

As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit http://www.eisai.com.  

References  

1. European Medicines Agency. Summary of Opinion (post authorisation) Halaven, eribulin April 2016. Available at: http://www.ema.europa.eu/docs/en_GB/docu...

2. Schöffski P et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. The Lancet. 2016

3. National Cancer Institute - http://www.cancer.org/cancer/sarcoma-adultsofttissuecancer/d...

4. ESMO Guidance. Available at: http://annonc.oxfordjournals.org/content...  Accessed: November 2015

5. Macmillan. What are soft tissue sarcomas? Available at: http://www.macmillan.org.uk/Cancerinform... .  Accessed: November 2015

6. SPC Halaven (updated November 2015). Available at: http://www.medicines.org.uk/emc/medicine...  Accessed: December 2015

7. Cancer Research UK, Soft Tissue Sarcoma Incidence Statistics. Available at: http://www.cancerresearchuk.org/cancer-info/cancerstats/type...    Accessed: November 2015

8. R. Pollock. Soft Tissue Sarcomas, A Volume in the American Cancer Society Atlas of Clinical Oncology Series. 2012

9. Fletcher et al. World Health Organization Classification of Tumours of Soft Tissue and Bone (4th Edition). Lyon: IARC Press, 2013

CONTACT: Media Enquiries: Eisai, Cressida Robson / Ben Speller,+44(0)7908-314-155 / +44-(0)7908-09416, Cressida_Robson@eisai.net /Ben_Speller@eisai.net; Tonic Life Communications, Alex Davies / CallumHaire, +44-(0)7716-324722 / +44-(0)7867-429-637, Alex.Davies@toniclc.com /Callum.Haire@toniclc.com